The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-Analysis

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are a critical member of systemic therapy for advanced non-small-cell lung cancer (NSCLC). Erlotinib is the first-generation EGFR-TKIs, the National Comprehensive Cancer Network (NCCN) guidelines recommend it as a first-line age...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Medicine (Baltimore)
Prif Awduron: Zhou, Jian-Guo, Tian, Xu, Cheng, Long, Zhou, Quan, Liu, Yuan, Zhang, Yu, Bai, Yu-ju, Ma, Hu
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Wolters Kluwer Health 2015
Pynciau:
5700
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4616758/
https://ncbi.nlm.nih.gov/pubmed/26448029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000001719
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg